Equinix May RAISE Margin Target and 4 More Analyst Insights

Equinix, Inc. (NASDAQ:EQIX): Following its checks, Wells Fargo believes Equinix will show bullish near-term guidance on demand as well as pricing on its analyst day, tomorrow. The firm thinks the company will heighten its long-term target for revenue and raise its long-term margin target. Wells Fargo remains bullish concerning the possibility of Equinix becoming REIT in upcoming years. The firm reiterates its Outperfomr rating on the stock.

Don’t Miss: Noon Buzz: Microsoft’s Surface Tablet, J.C. Penney Plummets 10%.

F5 Networks, Inc. (NASDAQ:FFIV): Lazard Capital reduced its estimates regarding F5 Networks when it discovered that the slowdown in the company’s SP segment could  be in more trouble than expected. Although Lazard Capital claims to be more cautious around the Q3 results of F5 Networks, the firm sees the company’s long-term fundamentals being unharmed. The firm maintains a Buy rating and lowers the price target to $133 on the stock.

Red Hat, Inc. (NYSE:RHT): Following the surveying of 50 resellers, Piper Jaffray thinks Red Hat will experience a a slow down in billings growth during Q1, compared to Q4. The firm states that the Red Hat partners who were surveyed completed almost 0.4% below the Q1 plan, but the firm maintains an Overweight rating since it thinks the company’s long-term outlook continues to be favorable.

Phillips-Van Heusen Corp. (NYSE:PVH): Goldman believe that PVH Corp will use its annual shareholder meeting on June 21 to restate its Q2 guidance of $1.18-$1.20 as well as its 2012 guidance of $6.15-$6.25. According to Goldman, the reaffirmed guidance should push shares up as a result of concerns about European exposure. The shares hold a Buy rating.

Celgene Corporation (NASDAQ:CELG): Canto Fitzgerald thinks that Celgene’s stock weakness results from concerns regarding the questionable outcome for E.U. approval of Celgene’s Revlimid in the front line/ first line setting. The firm predicts that Revlimid should be approved by the E.U. bye the end of the month. The firm also believes that even if the E.U. does not approve the drug, the growth rate for the company would fall only 2.5%. Cantor reiterates its Buy rating and $90 price target on shares.

Don’t Miss: Here’s Why a NEW Liquidmetal iPhone May Be On Its Way.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.